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Case Report

Bone scintigraphy imaging of cardiac amyloidosis
ABSTRACT
Transthyretin-related cardiac amyloidosis (ATTR) amyloidosis is an aggressive, rapidly progressive, and fatal disease, for which several
promising therapies are in development. This condition is frequently underdiagnosed because of the limited specificity of echocardiography
and the traditional requirement for histological diagnosis. It is well known that 99mtechnetium‑labeled bone scan radiotracers can localize in the
myocardial amyloid deposits, but the use of this imaging modality to differentiate between the two subtypes has only lately been revisited. We
report a case of a 76‑year‑old man with a clinical diagnosis of amyloidosis who underwent a bone scan that had features of ATTR amyloidosis.
To the best of our knowledge, this is the first case report in Sub‑Saharan Africa.
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INTRODUCTION
Cardiac amyloidosis is a rare cause of rapidly progressive,
restrictive cardiomyopathy and congestive heart
failure. [1] It is mostly difficult to diagnose and almost
always associated with poor prognosis. There are two
main subtypes of cardiac amyloidosis: transthyretin‑related
cardiac amyloidosis (ATTR) and cardiac light‑chain (AL)
amyloidosis.[2,3] Differentiating the two is important for
both prognosis and management, and this was only possible
through invasive biopsy procedures. Recently, however, a
few published cases have shown that bone scintigraphy is
able to reliably distinguish between the two.[4] In this case,
we report findings on the bone scan that supported the
diagnosis of ATTR cardiac amyloidosis.

Figure 1a and b shows the planar whole‑body bone scan
in the anterior projection [Figure 1a] and a zoomed
image [Figure 1b] demonstrating moderately intense cardiac
uptake with soft tissue uptake involving the shoulders, chest,
abdominal walls, and hips. Skeletal tracer uptake appears
mildly suppressed.
DISCUSSION
Cardiac amyloidosis is a rare cause of rapidly progressive,
restrictive cardiomyopathy and congestive heart failure.[1] It

CASE REPORT
A 76‑year‑old male who had clinical suspicion for
cardiac amyloidosis was referred to our department
for bone scintigraphy to try and differentiate between
the two main clinical subtypes. Planar whole‑body
images were performed in the anterior and posterior
projections 4 h after intravenous administration of
718 MBq (19.4 mCi) of 99mtechnetium (99mTc) methylene
diphosphonate (99mTc MDP).
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The bone scan images [Figure 1] demonstrated diffusely
increased tracer uptake in the heart and attenuated tracer
uptake throughout the bones. Increased tracer uptake was
also seen in the soft tissues of deltoid, gluteal, and abdominal
walls. No other site of abnormal tracer concentration was seen.
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or subcutaneous fat usually yields the diagnosis in 60%–80%
of patients with AL amyloidosis.[10] Unfortunately, a much
lower yield is observed in patients with ATTR amyloidosis
that requires for endomyocardial biopsy (EMB) to confirm
the diagnosis.[11] EMB has its own risks including myocardial
perforation, tamponade, and fatality. It also requires expertise
and this can introduce diagnostic delays.[12]
Cardiac magnetic resonance imaging (CMR) is a more
discriminating method for cardiac amyloidosis but does not
differentiate types of amyloidosis and cannot be performed
in the presence of implanted devices.[13] All of these factors
contribute to under diagnosis, which is crucial given the
poor prognosis of AL and ATTR cardiac amyloidosis and
the increasing availability of novel therapies for both
subtypes.[14,15]
a

b

Figure 1: (a and b) shows the planar whole-body bone scan in the anterior
projection (a) and a zoomed image (b) demonstrating moderately intense
cardiac uptake with soft tissue uptake involving the shoulders, chest,
abdominal walls, and hips. Skeletal tracer uptake appears mildly suppressed

is mostly difficult to diagnose and almost always associated
with poor prognosis. There are two main subtypes of cardiac
amyloidosis: transthyretin‑related cardiac amyloidosis (ATTR)
and cardiac light‑chain (AL) amyloidosis.[2,3] ATTR amyloidosis
may be acquired and hereditary that is either associated with
variants in the transthyretin gene or associated with wild‑type
transthyretin (also called senile systemic amyloidosis).
Cardiac AL amyloidosis is more rapidly progressive than
the ATTR type where the former is associated with >50%
mortality within 6 months after the diagnosis while the
ATTR subtype has a favorable prognosis of 98% 2‑year
survival.[5,6] The treatment options for the two subtypes
are also different with AL subtype likely to benefit from
cytotoxic chemotherapy,[7] while more novel therapies are
used for ATTR including inotersen, which was recently
approved by the FDA for the treatment of hereditary ATTR
amyloidosis polyneuropathy.[8] Differentiating the type of
cardiac amyloidosis (ATTR or AL) is thus vital in guiding
patient management.
Because cardiac amyloidosis has nonspecific clinical
symptoms as well as nonspecific electrocardiogram and
echocardiographic findings, [9] it remains a diagnostic
challenge and is often underdiagnosed. The gold standard for
the diagnosis of amyloidosis is through biopsy of a clinically
affected organ, with Congo red histology demonstrating
green birefringence. However, when amyloidosis is
clinically suspected, biopsy of the salivary glands, rectum,

Radionuclide bone scans with 99mTc‑labeled bisphosphonates
have been anecdotally reported to localize cardiac amyloid
deposits, although the molecular basis for this remains
unknown.[16] The cardiac uptake on the planar images is
visually scored using the Perugini grading system.[17] Briefly,
it is categorized as follows: Grade 0 – no cardiac uptake
and normal bone uptake; Grade 1 – cardiac uptake which is
less intense than the bone signal; Grade 2 – cardiac uptake
with intensity similar or greater than bone signal; and
Grade 3 – cardiac uptake with much attenuated or absent
bone signal. An uptake of Grade 2 and above is considered
significant.[17] A systematic evaluation of bone scans of
857 patients with histologically proven amyloid revealed
that cardiac ATTR amyloidosis can be reliably diagnosed in
the absence of histology provided that all of the following
criteria are met: heart failure with an echocardiogram or CMR
that is consistent with or suggestive of amyloidosis, Grade 2
or 3 cardiac uptake on a radionuclide scan with 99mTc‑labeled
3,3‑diphosphono‑1,2‑propanodicarboxylic acid (99mTc‑DPD),
99m
Tc‑labeled pyrophosphate (99mTc‑PYP), or 99mTc‑labeled
hydroxymethylene diphosphonate, and absence of a
detectable monoclonal protein.[4] More recently, studies[18,19]
have shown that 99mTc‑labeled MDP can also preferentially
bind to ATTR as similar to 99mTc PYP and 99mTc DPD.
Given that 99mTc‑MDP is more readily available than DPD
or PYP and already in use for routine bone scans, it would
provide a more feasible option in this diagnostic algorithm.
Unfortunately, cardiac localization of radiotracers also occurs
in a small proportion of patients with AL amyloidosis, and
although it is usually low grade, it can confound distinguishing
between cardiac AL and ATTR subtypes.[20] A recent study by
Hutt et al.[21] that had a cohort of 321 patients with suspected
cardiac amyloidosis that used 99mTc DPD as the radiotracer
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demonstrated that in addition to the intense cardiac uptake
in patients with ATTR, these patients also demonstrated
extensive soft tissue uptake in the deltoid, abdominal wall,
and gluteal muscles that was not seen in the AL amyloidosis
patients. They concluded that the soft tissue uptake in those
sites is specific to ATTR. Our patient demonstrated intense
cardiac uptake in addition to soft tissue uptake in the deltoid,
gluteal, and abdominal wall muscles that is relatively specific
to ATTR amyloidosis.
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CONCLUSION
Several studies[4,20] have concluded that cardiac transthyretin
amyloidosis can be reliably diagnosed in the absence of
histology provided that all of the following criteria are
met: heart failure with an echocardiogram or CMR that
is consistent with or suggestive of amyloidosis, intense
cardiac uptake on a 99mTc labeled bisphosphonate bone scan,
no detectable monoclonal protein in serum with normal
serum‑free light chains. AL amyloidosis is unlikely in any
patient satisfying all the above criteria. Invasive EMB can
therefore be avoided in elderly patients who satisfy these
criteria. In this regard, 99mTc‑labeled bisphosphonate bone
scans serve an integral role in the workup of patients with
suspected cardiac amyloidosis. Histological confirmation and
typing of amyloid should be sought in all cases of suspected
cardiac amyloidosis in whom these criteria are not met.
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